Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569723 | 0.89 | HSP90AB1 (0.30) | — | |
| SCHEMBL25667794 | 0.86 | CYP2A6 (0.36) | CYP2A6TRPV3CA2CA12ADRB3 | |
| SCHEMBL25570132 | 0.85 | CYP2A6 (0.39) | CYP2A6TRPV3CA2CA12ADRB3 | |
| SCHEMBL25667790 | 0.84 | TRPV3 (0.38) | CYP2A6TRPV3CA2CA12ADRB3 | |
| SCHEMBL25569709 | 0.84 | CYP2A6 (0.36) | CYP2A6TRPV3CA2CA12ADRB3 | |
| SCHEMBL30430218 | 0.84 | CYP2A6 (0.37) | CYP2A6TRPV3CA2CA12PTPRC | |
| SCHEMBL25569706 | 0.84 | CYP2A6 (0.37) | CYP2A6TRPV3CA2CA12PTPRC | |
| SCHEMBL25570141 | 0.83 | TRPV3 (0.38) | CYP2A6TRPV3CA2CA12ADRB3 | |
| SCHEMBL25667832 | 0.83 | CYP2A6 (0.37) | CYP2A6TRPV3CA2CA12ADRB3 | |
| SCHEMBL25569718 | 0.83 | CYP2A6 (0.37) | CYP2A6TRPV3CA2CA12ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | CYP2A6 1879/4885TRPV3 473/4885CA2 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.